Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the epithelial ovarian cancer market?
Recent years have seen rapid expansion in the market size of epithelial ovarian cancer. Predictions are that it will escalate from $2.08 billion in 2024 to $2.42 billion in 2025 with a compound annual growth rate (CAGR) of 16.5%. Factors contributing to this growth during the historical period include an increased demand for individualized cancer treatments, a surge in global healthcare spending, a growing preference for minimally invasive surgeries, an increase in the number of survivors of ovarian cancer, a surging interest in gene therapies, and a rising demand for palliative care services.
What will be the epithelial ovarian cancer market size in the future?
Expectations are high for substantial expansion of the epithelial ovarian cancer market in the coming years. The prediction is for it to inflate to a value of $4.41 billion by 2029, boasting an impressive compound annual growth rate (CAGR) of 16.1%. Factors contributing to this positive forecast range from increasing numbers of ovarian cancer cases, a growing elderly population, enhanced ovarian cancer awareness, larger investments in cancer research, and escalated government efforts to fight cancer. Noteworthy trends likely to impact the market during this time consist of improvements in medical imaging technology, the appearance of advanced molecular diagnostic tools, partnerships among pharmaceutical companies, swift integration of AI and machine learning into diagnostic tools, and the proliferating incorporation of robotic methods in surgeries.
Get your epithelial ovarian cancer market report here!
https://www.thebusinessresearchcompany.com/report/epithelial-ovarian-cancer-global-market-report
What main drivers are fueling expansion in the epithelial ovarian cancer market?
The growth of the epithelial ovarian cancer market is anticipated to be driven by the rising incidence of ovarian cancer. This form of cancer begins in the ovaries, specifically affecting the epithelial cells covering the ovarian surface. Factors such as an aging demographic, improved awareness and increased detection rates, in addition to genetic and lifestyle components contribute to the escalating incidence of ovarian cancer. Treatment for epithelial ovarian cancer is crucial, being the predominant and intensely aggressive form of ovarian cancer aimed at attacking malignant cells to bolster patient survival rates and outcomes. For example, the World Ovarian Cancer Coalition, a non-profit organization based in Canada, forecasted in February 2024 that the worldwide numbers of women diagnosed with ovarian cancer would climb by over 55% by 2050, measuring 503,448. The annual mortality rate owing to ovarian cancer is predicted to escalate to 350,956, marking about a 70% rise from the numbers in 2022. Consequently, the swelling incidence of ovarian cancer is anticipated to stimulate the expansion of the epithelial ovarian cancer market in the future.
What key areas define the segmentation of the global epithelial ovarian cancer market?
The epithelial ovarian cancer market covered in this report is segmented –
1) By Type Of Treatment: Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Surgery
2) By Drug Class: Platinum-based Chemotherapy Drugs, Poly(ADP-ribose) Polymerase Inhibitors, Bevacizumab, Chemotherapeutic Agents
3) By Stage Of Cancer: Early Stage, Advanced Stage
4) By Diagnosis Method: Imaging, Biopsy, Blood Tests
5) By End User: Hospitals, Clinics, Diagnostic Laboratories
Subsegments:
1) By Chemotherapy: Platinum-Based Chemotherapy, Non-Platinum Chemotherapy, Combination Chemotherapy
2) By Targeted Therapy: Monoclonal Antibodies, PARP Inhibitors, Angiogenesis Inhibitors, Other Targeted Agents
3) By Immunotherapy: Checkpoint Inhibitors, Cancer Vaccines, Adoptive T-Cell Therapy
4) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Progestins
5) By Surgery: Debulking Surgery, Oophorectomy, Hysterectomy, Other Surgical Procedures
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20778&type=smp
Who are the dominant players expanding their reach in the epithelial ovarian cancer market?
Major companies operating in the epithelial ovarian cancer market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Merck KGaA, Siemens Healthineers AG, Quest Diagnostics Incorporated, Eisai Co. Ltd., Genentech Inc., Qiagen N.V., Myriad Genetics Inc., Zymeworks Inc., Novogen Limited, Karyopharm Therapeutics Inc., Clovis Oncology Inc., ImmunoGen Inc., Fujirebio Diagnostics Inc., Vivesto AB
What are the key trends shaping the future of the epithelial ovarian cancer market?
Major companies operating in the epithelial ovarian cancer market are focusing on developing innovative treatment options, such as FRa-directed antibody-drug conjugates (ADCs), to specifically target folate receptor-alpha overexpressed on cancer cells, delivering potent cytotoxic agents while minimizing harm to healthy tissues. An FRa-directed antibody-drug conjugate (ADC) is a targeted cancer therapy that links an antibody specific to the folate receptor-alpha (FRa) to a cytotoxic drug, delivering the drug directly to cancer cells expressing this receptor. For instance, in November 2024, AbbVie Inc., a US-based biopharmaceutical company, received European Commission approval for ELAHERE (mirvetuximab soravtansine), a targeted treatment for adult patients with folate receptor-alpha (FRa) positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. ELAHERE provides a new, effective treatment option for patients who have received up to three prior systemic regimens. It targets a biomarker found in about one-third of ovarian cancer patients, enhancing the chance of survival and improving quality of life. The approval includes a companion diagnostic to identify suitable patients.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20778
Which regions are emerging as leaders in the epithelial ovarian cancer market?
North America was the largest region in the epithelial ovarian cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epithelial ovarian cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Ovarian Cancer Drugs Global Market Report 2025
https://thebusinessresearchcompany.com/report/ovarian-cancer-drugs-global-market-report
Polycystic Ovarian Syndrome Treatment Global Market Report 2025
Global Ovarian Cancer Drugs Global Global Market Report 2025
https://thebusinessresearchcompany.com/report/ovarian-cancer-drugs-market
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: